Pharming Group (US:PHAR) — Company Overview, News & Financial Data
Pharming Group develops innovative biopharmaceutical treatments focusing on rare diseases and therapies for hereditary angioedema.
About Pharming Group
Pharming Group (EURONEXT:PHARM), (NASDAQ:PHAR) is a biopharmaceutical company engaged in the development, production, and commercialization of innovative treatments for rare diseases and unmet medical needs. Its portfolio focuses on therapies in the fields of hereditary angioedema and Pompe disease, leveraging its expertise in protein replacement therapies. The company is renowned for Ruconest®, its lead product for the treatment of hereditary angioedema. Pharming Group NV is dedicated to enhancing patient care and improving quality of life through continuous research and development. With a commitment to sustainability and ethical practices, Pharming aims to expand its product offering and reach to address the needs of patients globally, striving for excellence in everything they do, with the ultimate goal of becoming a beacon of hope for those facing rare and challenging diseases.
Snapshot
Operations
Products and/or services of Pharming Group
- Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema treatment.
- Leniolisib, an oral treatment for activated phosphoinositide 3-kinase delta syndrome under investigation.
- Development of an alpha-glucosidase treatment for Pompe disease.
- Innovations in gene therapy aimed at providing long-term solutions for genetic disorders.
- Research in enzyme replacement therapies targeting rare diseases.
- Collaboration on COVID-19 treatment using recombinant human C1 esterase inhibitor.
Pharming Group executive team
- Mr. Fabrice Chouraqui Ph.D., Pharm.D.CEO & Executive Director
- Mr. Kenneth Lynard EMBAChief Financial Officer
- Ms. Mireille Sanders M.Sc.Chief Operations Officer
- Ms. Susanne EmbletonInvestor Relations Manager
- Mr. Ruud Van OutersterpChief Legal & Compliance Officer
- Mr. Michael LevitanVP of Investor Relations & Corporate Communications
- Ms. Ines BernalChief People Officer
- Dr. Anurag Relan M.D., MPHChief Medical Officer
- Dr. Alexander Breidenbach M.B.A.Chief Business Officer
- Ms. Leverne MarshChief Commercial Officer